Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: paclitaxel|BIOLOGICAL: bavituximab|OTHER: laboratory biomarker analysis|OTHER: pharmacological study
Sponsor: University of Arizona
Collaborators: National Cancer Institute (NCI)